Introduction
============

Slow release is critically significant in drug delivery for minimizing the amount of drug lost before reaching the target. Shell structures and supports can be used for slow delivery of drugs and are usually made from organic materials. For example, liposomes,[@b1-ijn-5-639]--[@b3-ijn-5-639] microspheres,[@b4-ijn-5-639] polymeric shells,[@b5-ijn-5-639] and polymeric micelles[@b6-ijn-5-639],[@b7-ijn-5-639] have been well investigated. In constructing a drug delivery system from organic materials, the combinations of shell or support materials, targeting molecules, and drugs are restricted to ensure stability, targeting efficiency, and drug effect. Although, many supporting polymers are expensive, this restriction can be reduced by using carbon nanotubes (CNTs).[@b8-ijn-5-639] On the other hand, nanomedicine, which is an emerging bridge linking nanotechnology and advanced medical technology, involves the exploration of nanoscaled materials with the aim of developing novel types of drug carriers, imaging agents, sensors, etc.[@b9-ijn-5-639],[@b10-ijn-5-639]

Nanotubes have several properties that make them suitable for use as nanotube-supported drugs. Functionalized CNTs have been shown in many studies to be able to cross cell membranes.[@b11-ijn-5-639]--[@b13-ijn-5-639] The ability of CNTs to cross cell membranes allowing them to be used as carriers is of particular high interest for drug delivery strategies. In targeting the delivery of drugs to cells, the drugs are first attached to the carrier by either covalent or noncovalent bonding. The drug carrier conjugates are then directed to the targeted cells via passive targeting methods (ie, a methodology to increase the target/nontarget ratio of the amounts of drugs delivered primarily by minimizing nonspecific interactions with nontarget organs, tissues, and cells) or active targeting methods (ie, the method by which the therapeutic agent is delivered to tumors by attaching the agent with a ligand that binds to specific receptors that are overexpressed on target cells).[@b14-ijn-5-639] After reaching the targeted site (organs, tissues, or cells), there are 2 possibilities: (1) the drug is internalized (ie, enters the cells) without internalization of the carrier or (2) both the drug and the carrier are internalized. The latter internalization method has greater delivery efficacy because after entering the cells, the intracellular environment will degrade the drug--carrier conjugate, releasing drug molecules inside the cells. On the other hand, in the former internalization method, the extracellular environment helps degrade drug--carrier conjugates, and the drug will then cross the lipid membrane to enter the cells. CNTs with the ability to cross cell membranes are good candidates to serve as drug delivery carriers to cells with high efficacy.[@b15-ijn-5-639] Also, negative mutagenic and clastogenic potentials suggest that single-walled carbon nanotubes (SWCNTs) and single-walled carbon nanohorns (SWCNHs) are not carcinogenic. For example, the acute per oral toxicity of SWCNHs was found to be quite low.[@b16-ijn-5-639]--[@b18-ijn-5-639] The lethal dosage for rats was more than 2,000 mg/kg of body weight. Intratracheal instillation tests revealed that SWCNHs rarely damaged rat lung tissue in a 90-day test period, although black pigmentation due to the accumulation of SWCNHs was observed.[@b19-ijn-5-639] In recent years, biological applications for carbon nanomaterials, including SWCNHs and fullerene, have come under close scrutiny.[@b11-ijn-5-639],[@b20-ijn-5-639]--[@b24-ijn-5-639]

SWCNHs and SWCNTs have extensive surface areas. Multitudes of horn interstices in SWCNHs enable large numbers of guest molecules to be adsorbed in a nonbonded way; however, to the best of our knowledge, the covalent grafting of drugs to the SWCNT has not been reported so far. Herein, we report the ability of SWCNTs for the covalent grafting of drugs to their active sites ([Figure 1](#f1-ijn-5-639){ref-type="fig"}).

The medicinal standpoint of this present research is covalent grafting of drugs to SWCNTs, which can be considered a new method for potential drug delivery. This would be achievable by preparing several pastes that can be applied on the skin similar to a label. Hydrolysis reaction occurs, and the drug is absorbed through the skin long time intervals after the application of the paste.[@b25-ijn-5-639] This process, therefore, enables the slow administration of medications for longer periods. This can help patients who have problems associated with oral administration and injection of drugs.

The solubility of products obtained in this work is also an important subject. The solubility of SWCNTs in aqueous and organic solvents has been previously studied by functionalizing the SWCNTs with various organic moieties.[@b26-ijn-5-639]

Materials and methods
=====================

Materials
---------

The pure SWCNTs in their closed cap shape without functional groups were purchased from Petrol Co. (Tehran, Iran) ([Figure 2](#f2-ijn-5-639){ref-type="fig"}). SOCl~2~, HCl, H~2~SO~4~, HNO~3~, H~2~O~2~ (30 wt%, aq), deionized water, NaH (80%), anhydrous dimethylformamide (DMF), CaH~2~, anhydrous Na~2~SO~4~, and phosphate-buffered saline (PBS; pH = 1.3) were obtained from Sigma Aldrich and Merck. Cellophane membrane dialysis bag was purchased from Polymer Co. (Tehran/Iran). Drugs, such as amantadine, metformin, gabapentin, betahistine, dipyridamol, lisinopril, and atorvastatin, were purchased from Sobhan Darou Co. (Tehran, Iran).

Functionalization of SWCNTs
---------------------------

To functionalize the SWCNT with drugs having amino and/ or hydroxyl moieties, we followed a methodology already demonstrated by several literatures.[@b26-ijn-5-639]--[@b30-ijn-5-639]

The first step was cracking and oxidation of the SWCNTs. For every 0.1 g of full-length SWCNT, 50 mL mixture of 3:1 (vol/vol) concentrated H~2~SO~4~ and HNO~3~ was added, and the SWCNT--acid mixture was then subjected to reflux at temperature between 65°C and 70°C for 30 hours.

When the desired time had elapsed, the SWCNT--acid mixture was diluted with a minimum amount of deionized water (250 mL). The resulting diluted nanotube--acid mixture was then filtered using a 0.45 μm polytetrafluoro- ethylene filter (PTFE--millipore) to leave a SWCNT filter cake. The nanotubes were then rinsed with water until a pH above 5 was obtained. Final rinsing was done using ethanol, and the resulting filter cake was suspended in a 4:1 mixture of H~2~O~2~ (30 wt%, aq) and H~2~SO~4~. The suspension was refluxed for 2 hours at 70°C to crack the SWCNTs in shorter lengths and, thereby, produce a larger number of opened caps for carboxylation. Concentrated HCl was then added to the suspension and briefly sonicated to remove the metal catalyst,[@b27-ijn-5-639]--[@b29-ijn-5-639] which resulted in the introduction of terminal carboxyl functional groups, as indicated by infrared measurement (ν~(C=O)~ = 1,737 cm^−1^; spectrum A, [Figure 4](#f4-ijn-5-639){ref-type="fig"}). The precipitate was stored in a vacuum oven at 180°C to remove the water.

The second step was the generation of the acyl chloride functional groups by suspending the purified SWCNT (prepared from the first step) in a solution of freshly distilled thionyl chloride (SOCl~2~) and DMF, which was previously kept in anhydrous Na~2~SO~4~ for 72 hours and distilled in the presence of CaH~2~. The amounts used in this particular example were 20 mL SOCl~2~ and 1 mL DMF per 0.1 g of SWCNT. This suspension was stirred at 65°C for 24 hours. The solid was then separated by filtration and washed with superdried tetrahydrofuran (THF) to remove excess of SOCl~2~. Subsequently, it was dried in vacuum at room temperature for 5 minutes. The final product was then subjected to functionalization with various drugs.

Drugs having free OH, NH~2~, or NH groups (drug-to- SWCNT weight ratio was 15:1)[@b30-ijn-5-639] were mixed with 1 mL solution of DMF and NaH (80%) and then stirred for 1 hour. The obtained acyl chloride SWCNTs were then added to the suspension. The reaction mixture was kept at 120°C for 5 days. The solid was then separated by filtration and washed with deionized water for several times.

The reaction of the drugs with SWCNT and the potential structure of grafted drugs to SWCNTs are summarized in [Table 1](#t1-ijn-5-639){ref-type="table"}.

After stirring, a black solid was obtained, which was soluble in DMF and dimethylsulfoxide (DMSO), less soluble in H~2~O and CH~3~CN, and insoluble in CHCl~3~, CH~2~Cl~2~, acetone, diethyl ether, and hexane ([Figure 3A and B](#f3-ijn-5-639){ref-type="fig"}).

Results and discussion
======================

We characterized the functional groups present in the covalent drugs grafted to SWCNT by IR and UV--visible (UV--vis) spectroscopy and transmission electron microscopy (TEM) methods after various treatments.

After the initial acid treatment of SWCNT with a mixture of H~2~SO~4~ and HNO~3~ followed by HCl, the spectrum A was observed ([Figure 4](#f4-ijn-5-639){ref-type="fig"}). The IR spectrum B is pertaining to pure betahistine, and the IR spectrum C ([Figure 3](#f3-ijn-5-639){ref-type="fig"}) shows the grafted SWCNT--betahistine (entry 4b, [Table 1](#t1-ijn-5-639){ref-type="table"}). The band corresponding to the carboxylic groups present in the acid-treated SWCNT (1,737 cm^−1^; IR spectrum A, [Figure 4](#f4-ijn-5-639){ref-type="fig"}) is gradually replaced by bands corresponding to amide bonds (1,663 cm^−1^; IR spectrum C, [Figure 4](#f4-ijn-5-639){ref-type="fig"}). Band at 1,699 cm^−1^ is attributed to water (IR spectrum A, [Figure 4](#f4-ijn-5-639){ref-type="fig"}). [Table 2](#t2-ijn-5-639){ref-type="table"} summarizes the main bands observed in IR spectra of grafted drugs to SWCNTs.

The UV--vis absorption spectrum of betahistine ([Figure 5](#f5-ijn-5-639){ref-type="fig"}) displays a loss of features compared with that of SWCNT indicating a disruption in the electronic structure of nanotubes due to the adsorption of betahistine on SWCNT.

TEM studies have revealed the successful grafting of betahistine and other drugs to SWCNT ([Figure 6](#f6-ijn-5-639){ref-type="fig"}). A large number of the bundles are abundant in functionalized SWCNTs, which are indicated by arrows.

*In vitro* release of betahistine from grafted SWCNT--betahistine
-----------------------------------------------------------------

Drug releasing from the grafted SWCNT--drug is indeed a hydrolysis reaction, which involves breaking of amide bond in acidic buffer (PBS; pH = 1.3) at 37°C. The powdered grafted SWCNT--betahistine (0.02 g) was added into a cellophane membrane dialysis bag. The bag was closed and transferred into a flask containing 50 mL of acid buffer. The release of betahistine from grafted SWCNT--betahistine was followed by UV--vis spectroscopy. [Figure 7A](#f7-ijn-5-639){ref-type="fig"} illustrates the cumulative dose of betahistine released from grafted SWCNT--betahistine.

Drug loading of betahistine
---------------------------

A weighed quantity of microspheres was hydrolyzed in 50 mL acid buffer (PBS; pH = 1.3). After suitable dilution, the absorbance of samples was measured by UV--vis spectrophotometer at *λ* = 264 nm. The amount of drug was determined from the standard plot of betahistine. The amount of betahistine loaded in SWCNTs' microspheres was determined after complete hydrolysis and was found to be 73 wt%.

*In vitro* release of dipyridamol from grafted SWCNT--dipyridamol
-----------------------------------------------------------------

The release of dipyridamol from the grafted SWCNT-- dipyridamol was studied using the same method, which has been described earlier for SWCNT--betahistine. [Figure 7B](#f7-ijn-5-639){ref-type="fig"} illustrates the cumulative dose of dipyridamol released from grafted SWCNT--dipyridamol.

Drug loading of dipyridamol
---------------------------

Drug loading of dipyridamol (*λ* = 262 nm was studied using the same method, which has been described earlier for SWCNT--betahistine, and was found to be 65 wt%. It is interesting to note that the release of dipyridamol from SWCNTs was achieved more smoothly than that of betahistine from SWCNT--betahistine. This can be easily deduced by comparing [Figure 7A](#f7-ijn-5-639){ref-type="fig"} with [Figure 7B](#f7-ijn-5-639){ref-type="fig"}.

Conclusion
==========

In summary, the covalent grafting of some known drugs with different pharmaceutical activities to SWCNTs was achieved by the formation of amides and esters from the drugs having free hydroxyl and/or amino groups mixed with the prepared acyl chloride in SWCNTs. The covalent grafting of drugs increases the solubility of SWCNTs in both aqueous and organic solvents. *In vitro* release of betahistine and dipyridamol from their corresponding grafted SWCNT adducts was studied, which indicates that drug release can occur smoothly from covalent SWCNT--drug adducts during long time intervals, and this can be considered a useful method for drug delivery.
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###### 

Covalent grafting of various drugs to SWCNT

  -----------------------------------------------------------------------
  Entry   Drug scaffold (a)   Drug name (properties)        Product (b)
  ------- ------------------- ----------------------------- -------------
  1       Amantadine\         Antiviral and antiparkinson   

  2       Metformin\          Antidiabetic                  

  3       Gabapentin\         Antiepileptic                 

  4       Betahistine\        Antivertigo                   

  5       Dipyridamol\        Antiplatelet                  

  6       Lisinopril\         Antihypertensive              

  7       Atorvastatin\       Blood cholesterol lowering    
  -----------------------------------------------------------------------

###### 

Infrared absorption bands obtained from the acid-treated SWCNTs and drugs grafted to SWCNTs' solid samples

  Compound     Region (cm^−1^)   Band assignments
  ------------ ----------------- ----------------------------------------------------
  SWCNT-COOH   1,737             Carboxylic acid C=O stretching vibration of SWCNTs
               3,407             Carboxylic acid OH stretching vibration of SWCNTs
  1b           1,630             Amide C=O stretching vibration
  2b           1,660             Amide C=O stretching vibration
  3b           1,630             Amide C=O stretching vibration
  4b           1,663             Amide C=O stretching vibration
  5b           1,626             Ester C=O stretching vibration
  6b           1,656             Amide C=O stretching vibration
  7b           1,713             Ester C=O stretching vibration
